Two Sigma Advisers’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Two Sigma Advisers’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-90,300	Closed	-$1.6M	–	2538
2018 Q3	$1.6M	Buy	90,300 +40,000	+80%	+$687K	﹤0.01%	1327
2018 Q2	$694K	Buy	+50,300	New	+$597K	﹤0.01%	1783

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Two Sigma Advisers's ECYT Position: Q4 2018 in Review

Two Sigma Advisers sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 90,300 shares — an estimated $1.6M sold.

Two Sigma Advisers first reported a position in ECYT in Q2 2018 and held it in 2 quarters. The position peaked at $1.6M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Two Sigma Advisers reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Two Sigma Advisers sold 90,300 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $1.6M.
Two Sigma Advisers first reported a position in Endocyte, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
Two Sigma Advisers's Endocyte, Inc. Common Stock position peaked at $1.6M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Two Sigma Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.